Related Experiment Video
Updated: Aug 19, 2026

Electrochemiluminescence Assays for Human Islet Autoantibodies
Published on: March 23, 2018
Autoantibodies against oxidized LDLs and atherosclerosis in type 2 diabetes
Francesco Piarulli1, Annunziata Lapolla, Giovanni Sartore
1Department of Medical and Surgical Sciences, University of Padova, Ospedale dei Colli, Via dei Colli 4, 35100 Padova, Italy. francesco.piarulli@unipd.it
Objective:
The aim of our study was to examine, in type 2 diabetic patients, the relationship between autoantibodies against oxidatively modified LDL (oxLDL Ab) and two indexes of atherosclerosis, intimal-medial thickness of the common carotid artery (CCA-IMT), which reflects early atherosclerosis, and the ankle-brachial index (ABI), which reflects advanced atherosclerosis.
Research Design And Methods:
Thirty newly diagnosed type 2 diabetic patients, 30 type 2 diabetic patients with long duration of disease, and 56 control subjects were studied. To detect oxLDL Ab, the ImmunoLisa Anti-oxLDL Antibody ELISA was used. ABI was estimated at rest by strain-gauge plethysmography. Carotid B-mode imaging was performed on a high-resolution imaging system (ATL HDI 5000).
Results:
In patients with long duration of disease, IgG oxLDL Ab were significantly higher and ABI significantly lower compared with the other two groups. We found a correlation between IgG oxLDL Ab and CCA-IMT in all diabetic patients. A significant inverse correlation between IgG oxLDL Ab and ABI only in patients with long duration of disease was seen, demonstrating a close relationship between these autoantibodies and advanced atherosclerosis.
Conclusions:
IgG OxLDL Ab may be markers of the advanced phase of the atherosclerotic process and the response of the immunological system to the oxLDL, which are present within atherosclerotic lesions.
Related Concept Videos
Type I Diabetes II: Pathophysiology
Type II Diabetes II: Pathophysiology
Coronary Artery Disease I: Introduction
Type I Diabetes I: Introduction
Type II Diabetes I: Introduction
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
